OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR

Category Primary study
JournalJournal of Clinical Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 691d9f3504ec22b5f14a301b576d83828b62f114
First added on: Feb 10, 2025